Evidence map›Paper›PMID 36371232›Full record

ArticleAlzheimer's research & therapy2022

Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.

Edward N Wilson, Christina B Young, Javier Ramos Benitez, Michelle S Swarovski, Igor Feinstein, Manu Vandijck, Yann Le Guen, Nandita M Kasireddy, Marian Shahid, Nicole K Corso and 28 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Circulating Biomarkers for the Early Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Analytical and clinical performance of eight SimoaAlzheimer's research & therapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 6 institutions in 2 countries.

Edward N WilsonNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA. enwilson@stanford.edu.
Christina B YoungNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Javier Ramos BenitezNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Michelle S SwarovskiNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Igor FeinsteinAnesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA, USA.
Manu VandijckFujirebio Europe NV, Ghent, Belgium.
Yann Le GuenNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Nandita M KasireddyNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Marian ShahidNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Nicole K CorsoNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Qian WangNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Gabriel KennedyNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Alexandra N TrellePsychology, Stanford University, Stanford, CA, USA.
Betty LindNeurology, Portland VA Medical Center, Portland, OR, USA.
Divya ChannappaNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Malia BelnapNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Veronica RamirezNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Irina Skylar-ScottNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Kyan YounesNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Maya V YutsisNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Nathalie Le BastardFujirebio Europe NV, Ghent, Belgium.
Joseph F QuinnNeurology, Portland VA Medical Center, Portland, OR, USA.
Christopher H van DyckPsychiatry, Yale University, New Haven, CT, USA.
Angus NairnPsychiatry, Yale University, New Haven, CT, USA.
Carolyn A FredericksNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Lu TianBiomedical Data Science, Stanford University, Stanford, CA, USA.
Geoffrey A KerchnerNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Thomas J MontinePathology, Stanford University, Stanford, CA, USA.
Sharon J ShaNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Guido DavidzonRadiology, Stanford University, Stanford, CA, USA.
Victor W HendersonNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Frank M LongoNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Michael D GreiciusNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Anthony D WagnerWu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.
Tony Wyss-CorayNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Kathleen L PostonNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Elizabeth C MorminoNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Katrin I AndreassonNeurology & Neurological Sciences, Stanford University, Stanford, CA, USA.
Stanford University · USNeurosciences Institute · USFujirebio (Belgium) · BEPortland VA Medical Center · USYale University · USStanford Medicine · US

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI SUMAN JAYADEV · 2020 to 2026
$29.0M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Jennifer Kaci Fairchild · 2020 to 2026
$29.0M
Research Education ComponentP30AG066518 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KEVIN M DUFF, Lisa C Silbert · 2020 to 2026
$28.6M
Working Memory in Parkinson Disease: A Cognitive & Systems Neuroscience ApproachP50AG047366 · NIA · STANFORD UNIVERSITY · PI HENDERSON, VICTOR · 2015 to 2019
$7.9M
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's diseaseR01NS115114 · NINDS · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I., POSTON, KATHLEEN LOMBARD · 2019 to 2023
$4.2M
The role of TREM1 signaling in the development of Alzheimer’s diseaseRF1AG053001 · NIA · STANFORD UNIVERSITY · PI ANDREASSON, KATRIN I. · 2016 to 2016
$2.0M
High-resolution imaging of hippocampal mechanisms in age-related memory decline.R01AG048076 · NIA · STANFORD UNIVERSITY · PI WAGNER, ANTHONY D · 2014 to 2018
$1.9M
Basal Ganglia Modulation of Cognitive Systems in Parkinson's diseaseK23NS075097 · NINDS · STANFORD UNIVERSITY · PI POSTON, KATHLEEN LOMBARD · 2011 to 2015
$936k
The impact of early medial temporal lobe Tau in human cognitive agingR21AG058859 · NIA · STANFORD UNIVERSITY · PI MORMINO, ELIZABETH · 2018 to 2019
$432k
"Eye-tracking and Multimodal Biomarkers to Enhance Detection of Preclinical Alzheimer's Disease in Diverse Populations."K99AG075184 · NIA · STANFORD UNIVERSITY · PI TRELLE, ALEXANDRA NICOLE · 2022 to 2023
$263k
NIA NIH HHS K99 AG075184NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG048076NIA NIH HHS R21 AG058859NIA NIH HHS RF1 AG053001NIA NIH HHS U24 AG021886NINDS NIH HHS K23 NS075097NINDS NIH HHS R01 NS115114
6 · The paper itself

Abstract

backgroundThe recent promise of disease-modifying therapies for Alzheimer's disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the development of novel blood-based biomarkers for AD have revealed that plasma levels of tau phosphorylated at various residues are specific and sensitive to AD dementia. However, the currently available tests have shortcomings in access, throughput, and scalability that limit widespread implementation.

methodsWe evaluated the diagnostic and prognostic performance of a high-throughput and fully-automated Lumipulse plasma p-tau181 assay for the detection of AD. Plasma from older clinically unimpaired individuals (CU, n = 463) and patients with mild cognitive impairment (MCI, n = 107) or AD dementia (n = 78) were obtained from the longitudinal Stanford University Alzheimer's Disease Research Center (ADRC) and the Stanford Aging and Memory Study (SAMS) cohorts. We evaluated the discriminative accuracy of plasma p-tau181 for clinical AD diagnosis, association with amyloid β peptides and p-tau181 concentrations in CSF, association with amyloid positron emission tomography (PET), and ability to predict longitudinal cognitive and functional change.

resultsThe assay showed robust performance in differentiating AD from control participants (AUC 0.959, CI: 0.912 to 0.990), and was strongly associated with CSF p-tau181, CSF Aβ42/Aβ40 ratio, and amyloid-PET global SUVRs. Associations between plasma p-tau181 with CSF biomarkers were significant when examined separately in Aβ+ and Aβ- groups. Plasma p-tau181 significantly increased over time in CU and AD diagnostic groups. After controlling for clinical diagnosis, age, sex, and education, baseline plasma p-tau181 predicted change in MoCA overall and change in CDR Sum of Boxes in the AD group over follow-up of up to 5 years.

conclusionsThis fully-automated and available blood-based biomarker assay therefore may be useful for early detection, diagnosis, prognosis, and treatment monitoring of AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersHumanstau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseaseBiomarkersPhospho-tauPlasma

Identifiers

PMID36371232
PMCPMC9652927
OpenAlexW4309073121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.